Dan Shu

Dan Shu

Dan Shu, PhD

Research Associate Professor
Unit / Department / Division
Pharmaceutics and Pharmacology
Email Address
Phone Number

Professional Interests

Professional Interests

Dr. Shu’s research is focused on (1) RNA nanotechnology: use RNA as a nanotechnology platform to construct RNA nanoparticles with functional modalities for therapeutics, targeting, and diagnostics (ACS Nano, 2015; Nature Nanotechnology, 2011; Nano Letters, 2004); and (2) Single molecule biophysical studies: use single-molecule detection (such as FRET) to understand the structure-function relationship for individual biomolecules (ACS Nano, 2010; EMBO Journal, 2007; RNA, 2007). Her long-term objective is to focus on the development and translation of RNA nanotechnology-based therapeutics and imaging agents into clinical trials.


  • 1990, M.D., Tongji Medical University

Journal Articles

Shu D, Zhang L, Bai X, Yu J, Guo P. Stoichiometry of multi-specific immune checkpoint RNA Abs for T cell activation and tumor inhibition using ultra-stable RNA nanoparticles. Mol Ther Nucleic Acids. 2021 Mar 13;24:426-435. doi: 10.1016/j.omtn.2021.03.007. PMID: 33868786; PMCID: PMC8042240.

Shah H, Pang L, Wang H, Shu D, Qian SY, Sathish V. Growth inhibitory and anti-metastatic activity of epithelial cell adhesion molecule targeted three-way junctional delta-5-desaturase siRNA nanoparticle for breast cancer therapy. Nanomedicine. 2020 Nov;30:102298. doi: 10.1016/j.nano.2020.102298. Epub 2020 Sep 12. PMID: 32931930; PMCID: PMC7680439.

Pang L, Shah H, Wang H, Shu D, Qian SY, Sathish V. EpCAM-Targeted 3WJ RNA Nanoparticle Harboring Delta-5-Desaturase siRNA Inhibited Lung Tumor Formation via DGLA Peroxidation. Mol Ther Nucleic Acids. 2020 Aug 25;22:222-235. doi: 10.1016/j.omtn.2020.08.024. PMID: 33230429; PMCID: PMC7515975.

Yin H, Xiong G, Guo S, Xu C, Xu R, Guo P, Shu D. Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133. Mol Ther. 2019 Jul 3;27(7):1252-1261. doi: 10.1016/j.ymthe.2019.04.018. Epub 2019 Apr 25. PMID: 31085078; PMCID: PMC6612664.

Xu Y, Pang L, Wang H, Xu C, Shah H, Guo P, Shu D, Qian SY. Specific delivery of delta-5-desaturase siRNA via RNA nanoparticles supplemented with dihomo-γ- linolenic acid for colon cancer suppression. Redox Biol. 2019 Feb;21:101085. doi: 10.1016/j.redox.2018.101085. Epub 2018 Dec 18. PMID: 30584980; PMCID: PMC6305700.

Shu Y, Yin H, Rajabi M, Li H, Vieweger M, Guo S, Shu D, Guo P. RNA-based micelles: A novel platform for paclitaxel loading and delivery. J Control Release. 2018 Apr 28;276:17-29. doi: 10.1016/j.jconrel.2018.02.014. Epub 2018 Feb 14. PMID: 29454064; PMCID: PMC5964609.

Smith JA, Braga A, Verheyen J, Basilico S, Bandiera S, Alfaro-Cervello C, Peruzzotti-Jametti L, Shu D, Haque F, Guo P, Pluchino S. RNA Nanotherapeutics for the Amelioration of Astroglial Reactivity. Mol Ther Nucleic Acids. 2018 Mar 2;10:103-121. doi: 10.1016/j.omtn.2017.11.008. Epub 2017 Nov 24. PMID: 29499926; PMCID: PMC5738063.

Xu C, Haque F, Jasinski DL, Binzel DW, Shu D, Guo P. Favorable biodistribution, specific targeting and conditional endosomal escape of RNA nanoparticles in cancer therapy. Cancer Lett. 2018 Feb 1;414:57-70. doi: 10.1016/j.canlet.2017.09.043. Epub 2017 Oct 5. PMID: 28987384; PMCID: PMC5844565.

Yang X, Xu Y, Wang T, Shu D, Guo P, Miskimins K, Qian SY. Erratum to "Inhibition of cancer migration and invasion by knocking down delta-5-desaturase in COX-2 overexpressed cancer cells" [Redox Biol. 11 (2017) 653-662]. Redox Biol. 2017 Aug;12:1062. doi: 10.1016/j.redox.2017.03.021. Epub 2017 Apr 12. Erratum for: Redox Biol. 2017 Apr;11:653-662. PMID: 28410935; PMCID: PMC5975204.

Lee TJ, Yoo JY, Shu D, Li H, Zhang J, Yu JG, Jaime-Ramirez AC, Acunzo M, Romano G, Cui R, Sun HL, Luo Z, Old M, Kaur B, Guo P, Croce CM. RNA Nanoparticle-Based Targeted Therapy for Glioblastoma through Inhibition of Oncogenic miR-21. Mol Ther. 2017 Jul 5;25(7):1544-1555. doi: 10.1016/j.ymthe.2016.11.016. Epub 2017 Jan 18. PMID: 28109960; PMCID: PMC5498802.